Ministry of Health (Saudi Arabia)

Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines

Thursday, October 21, 2021 - 2:47pm

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.

Key Points: 
  • In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.
  • The two candidate vaccines, based on GSKs proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.
  • Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses.
  • Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan.

Wysa, the Leading AI-Powered Mental Health Platform Welcomes New Senior Executive Members

Wednesday, October 13, 2021 - 3:00pm

Zereana will lead the roll out and management of Wysa's US-based therapy network in support of Wysa's AI + expert human model.

Key Points: 
  • Zereana will lead the roll out and management of Wysa's US-based therapy network in support of Wysa's AI + expert human model.
  • "As a society, we must reimagine the way we think about mental health care.
  • Wysa is a global leader in AI-driven mental health support, available both to individuals and through employer benefits programs.
  • For employers, Wysa offers a workplace solution that caters to the full spectrum of mental health needs.

Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease

Monday, October 11, 2021 - 2:29am

Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital.

Key Points: 
  • Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital.
  • The AI will be used in clinical field research to estimate the presence or absence of abnormal heart movements based on the data of patients undergoing electrocardiographic procedures at the University of Tokyo Hospital.
  • Based on the electrocardiogram data of patients examined at the University of Tokyo Hospital, Fujitsu and the University of Tokyo Hospital will verify the effectiveness of detection of abnormal heart movement by AI.
  • Through its joint research with the University of Tokyo Hospital, Fujitsu will continue to actively promote research and development of AI to detect various heart diseases.

CH GROUP ANNOUNCES AMERICAN FOOTBALL AND SPORTS MEDICINE INITIATIVES IN CELEBRATION OF 91ST SAUDI NATIONAL DAY

Thursday, October 7, 2021 - 8:03pm

Commenting on the Initiatives, CH Group Chairman/CEO Elsayed Zayan stated, Allow me first to share congratulations regarding celebration of the Kingdoms 91st anniversary from its founding.

Key Points: 
  • Commenting on the Initiatives, CH Group Chairman/CEO Elsayed Zayan stated, Allow me first to share congratulations regarding celebration of the Kingdoms 91st anniversary from its founding.
  • CH Group is proud to be a partner in Saudi Arabias social and economic growth as A Home for Us.
  • This announcement will be followed by a VIP Diplomatic Trip to Saudi Arabia by US participants in the Initiatives.
  • The CH family of companies and affiliates (CH Group) encompass a diversified conglomerate engaged in a variety of multi-national business products, services and solutions.

Canadian Vaping Association: Canadian health groups have abandoned the progressive harm reduction strategies of other Commonwealth nations

Thursday, September 9, 2021 - 9:39pm

It is no wonder that Canadians are confused about the risk and efficacy of vaping products, given the advice from each countrys health organizations varies so widely.

Key Points: 
  • It is no wonder that Canadians are confused about the risk and efficacy of vaping products, given the advice from each countrys health organizations varies so widely.
  • Although Health Canada states that vaping is less harmful than smoking, groups such as Physicians for a Smoke-Free Canada (PSFC), who are funded by the Canadian government, continue to intentionally conflate nicotine vaping with tobacco.
  • Public Health England (PHE) continues to reaffirm its assessment that vaping is at least 95% less harmful than smoking.
  • Continuing to conflate vaping with tobacco and the systematic denial of the science on vaping by these health groups, has caused Canada to lag behind other Commonwealth nations in eliminating tobacco use.

Ghana Public Health Sector Enables Efficient COVID-19 Response Readiness with GhiLMIS

Tuesday, August 31, 2021 - 1:00pm

This has had significant positive impacts on operations in the shortest period of time which enabled, and continues to enable, COVID-19 response readiness.

Key Points: 
  • This has had significant positive impacts on operations in the shortest period of time which enabled, and continues to enable, COVID-19 response readiness.
  • "As a fully deployed digitized, country wide network, GhiLMIS has enabled the Ghana MoH to react quickly and fully support COVID-19 pandemic response measures.
  • "The interruptions caused by the pandemic created a critical need to ensure that the Ghana's public health supply chain are activated," said Philip Lule, GhilMIS implementation lead and CEO for Systems for Development (S4D).
  • Leading global organizations have joined One Network transforming industries like Retail, Food Service, Consumer Goods, Automotive, Healthcare, Public Sector, Telecom, Defense, and Logistics.

Kuwait Central Blood Bank Chooses Biolog Transfusion Solution to Upgrade Blood Components’ Management

Tuesday, August 31, 2021 - 10:51am

After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.

Key Points: 
  • After a public consultation, biolog-id, a global service provider of connected healthcare solutions, through its local partner ATC, has been awarded by the Ministry of Health to deploy Biolog Transfusion Solution in Kuwait Central Blood Bank (KCBB), the national blood bank operator.
  • While the COVID-19 pandemic has challenged the transfusion supply chain, KCBB has chosen to adopt the cutting-edge technology Biolog Transfusion Solution to better drive its operations.
  • Biolog Transfusion Solution will be deployed in the Kuwait Central Blood Bank as well as three distant Blood Banks.
  • About Kuwait Central Blood Bank:
    The Kuwait Central Blood Banks (KCBB) mission is meeting the countrys needs of the patients for safe, high quality and provision of all transfusion services under the supervision of the government.

Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan

Thursday, August 26, 2021 - 1:00pm

The MHLW accreditation of Orphan Drug Designation follows the Japanese Pharmaceutical Affairs & Food Sanitation Councils (PAFSC) First Committee on Drugs agreement on July 28 to grant orphan drug designation for FINTEPLA for Dravet syndrome.

Key Points: 
  • The MHLW accreditation of Orphan Drug Designation follows the Japanese Pharmaceutical Affairs & Food Sanitation Councils (PAFSC) First Committee on Drugs agreement on July 28 to grant orphan drug designation for FINTEPLA for Dravet syndrome.
  • The PAFSC is organized under the MHLW and consists of several expert committees from various fields, who serve as the decision-making body for drug approval (J-NDA, s-NDA) as well as Orphan Drug designation.
  • In Japan, Orphan Drug Designation may be granted to drug candidates designed to treat diseases with fewer than 50,000 patients or diseases that are designated as intractable and the need for improved medical care is high.
  • The orphan drug designation of FINTEPLA in Japan is an important milestone in our mission to meet the unmet needs of severe, rare epilepsy patients around the world, said Stephen J. Farr, Ph.D., President and Chief Executive Officer of Zogenix.

Achiko’s Rapid Covid-19 Diagnostic Test AptameX™ Receives Product and Registration Approval from Indonesia’s Ministry of Health

Wednesday, August 25, 2021 - 12:30pm

AptameX, Achikos breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister digital passporting service, Teman Sehat(Health Buddy).

Key Points: 
  • AptameX, Achikos breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister digital passporting service, Teman Sehat(Health Buddy).
  • 53 LR Achiko AG (SWX: ACHI, ISIN CH0522213468) through PT Achiko Medika Indonesia (Achiko, the Company), is pleased to announce that the Ministry of Health of the Republic of Indonesia has granted product and registration approval for its proprietary low-cost, rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service, Teman Sehat (Health Buddy).
  • Achikos 50%-subsidiary, PT Achiko Medika Indonesia, and PT Indofarma TBK (Indofarma) have entered into an agreement to manufacture AptameXand have received product registration approval in Indonesia.
  • The approval opens the door to the rapid scale-up of production and sale of Achikos AptameXtest kits in Indonesia.

Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Monday, August 23, 2021 - 1:30pm

We are grateful to the community of patients, caregivers and physicians whose efforts have contributed to this important approval.

Key Points: 
  • We are grateful to the community of patients, caregivers and physicians whose efforts have contributed to this important approval.
  • Outside of the U.S., patients have had access to Dojolvi through named patient and early access programs.
  • LC-FAOD are a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to convert long-chain fatty acids into energy.
  • Other current treatment options for LC-FAOD include avoidance of fasting, low-fat/high-carbohydrate diets, carnitine and even-carbon medium-chain triglyceride (MCT) oil, a medical food product.